Abstract
Arsenic trioxide is an effective treatment for patients with acute promyelocytic leukaemia (APL) who have relapsed from or are refractory to all trans-retinoic acid and anthracycline chemotherapy. Cardiac effects observed include electrocardiographic changes such as QTc prolongation, T-wave abnormalities, torsades de pointes and sudden death. We describe a case of a man, 76 years old, who was admitted to our department for dyspnoea in APL in treatment with arsenic trioxide. Chest radiograph illustrated an enlarged cardiac silhouette and bilateral pleuric effusion and the ECG evidenced QT prolongation. The patient was also submitted to transthoracic echocardiography that revealed moderate pericardial effusion without signs of cardiac tamponade and a normal biventricular function. This condition was considered to be associated with arsenic trioxide polyserosit and the drug therapy was immediately discontinued and steroid drugs started. After 2 weeks of arsenic trioxide therapy suspension there was evidence of complete resolution of pericardial and pleuric effusion and the ECG showed normal QT interval.
This is a preview of subscription content, log in via an institution to check access.
References
Barbey, J. T., Pezzullo, J. C., & Soignet, S. L. (2003). Effect of arsenic trioxide on QT interval in patients with advanced malignancies. Journal of Clinical Oncology, 21, 3609–3615.
Shen, Z., Chen, G., & Ni, J. (1997). Use of arsenic trioxide in the treatment of APL, clinical efficacy and pharmacokinetics in relapsed patients. Blood, 89, 3354–3360.
Niu, C., Yan, H., Yu, T., et al. (1999). Studies on treatment of acute promyelocytic leukaemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood, 94, 3315–3324.
Soignet, S. L., Frankel, S. R., Douer, D., et al. (2001). United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. Journal of Clinical Oncology, 19, 3852–3860.
Westervelt, P., Brown, R. A., Adkins, D. R., Khoury, H., et al. (2001). Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide. Blood, 98, 266–271.
Tallman, M. S., Andersen, J. W., Schiffer, C. A., et al. (1997). All trans retinoid acid in acute promyelocytic leukemia. The New England Journal of Medicine, 337, 1021–1028.
Chanan-Khan, A., Srinivasan, S., & Czuczman, M. S. (2004). Prevention and management of cardiotoxicity from antineoplastic therapy. Journal of Supportive Oncology, 2(3), 251–256.
Jones, R. L., & Ewer, M. S. (2006). Cardiac and cardiovascular toxicity of nonanthracycline anticancer drugs. Expert Review of Anticancer Therapy, 6(9), 1249–1269.
Drolet, B., Simard, C., & Roden, D. M. (2004). Unusul effects of a QT-prolonging drug, arsenic trioxide, on cardiac potassium currents. Circulation, 109, 26–29.
Ghavamzade, A., Alimoghaddam, K., Ghaffari, S. H., et al. (2006). Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy. Annals of Oncology, 17, 131–134.
Klaassen, C. D. (2001). Heavy metals and heavy-metal antagonists. In J. G. Hardman, L. E. Limbird, & G. A. Goodman (Eds.), Goodman & Gilman’s the pharmacological basis of therapeutics (pp. 1851–1875). New York: McGraw-Hill.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Vizzardi, E., Zanini, G., Antonioli, E. et al. QT Prolongation: A Case of Arsenical Pericardial and Pleural Effusion. Cardiovasc Toxicol 8, 41–44 (2008). https://doi.org/10.1007/s12012-007-9009-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12012-007-9009-4